KKKwang Hyun Kim

Kwang Hyun Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kwang Hyun Kim has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Jeong Hun Hah

    Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

    7 shared publications
  • Myung-Whun Sung

    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

    5 shared publications
  • Tack-Kyun Kwon

    5 shared publications
  • Myung-Whun Sung

    Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University School of Medicine, Seoul, Korea

    4 shared publications
  • Wonjae Cha

    Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

    3 shared publications
  • Dae Seog Heo

    Patient-Centered Clinical Research Coordinating Center, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea

    2 shared publications

Latest Publications

    • 1 July 2015
      • Vol. 35  (7) , 4235-41

    Effect of Celecoxib on Survival of Mobile Tongue Cancer.

    by Doh Young Lee, Jae Hyun Lim, Yoon Joong Kim, Seong Dong Kim, Seok-Woo Park, Seong Keun Kwon, J Hun Hah, Tack-Kyun Kwon, Kwang Hyun Kim, Young Ho Kim, et al.

    The goal of the present study was to evaluate the effects of celecoxib on treatment outcomes of squamous cell carcinoma of the mobile tongue. Among 158 patients who were diagnosed with mobile tongue cancer, 19 received celecoxib during the preoperative, postoperative, or post-recurrence phase. Differences in disease-specific survival (DSS) and recurrence-free survival (RFS) between patients who received celecoxib (study group) and those who did not (control group) were analyzed. For the entire cohort, DSS and RFS were not significantly different according to duration of celecoxib treatment (p=0.293 and 0.703, respectively). Among patients who received chemotherapy, DSS was significantly higher in the study group than in the control group (p=0.048), but RFS was not different between the two groups (p=0.117). When combined with chemotherapy, celecoxib may have a beneficial effect on the survival of patients with mobile tongue cancer.


  • Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy

    by Yoojoo Lim, Bhumsuk Keam, Youngil Koh, Tae Min Kim, Se-Hoon Lee, J. Hun Hah, Tack-Kyun Kwon, Dong-Wan Kim, Hong-Gyun Wu, Myung-Whun Sung, et al.


  • PP156

    by Yoon Jong Ryu, Heejin Kim, Won Yong Lee, Hyo-Geun Choi, Dong Wook Kim, Yoon Chan Rah, Wonjae Cha, Soo-Youn An, J. Hun Hah, Tack-Kyun Kwon, et al.

  • Chemocauterization of the internal opening with trichloroacetic acid as first‐line treatment for pyriform sinus fistula

    by Wonjae Cha, Sung‐Woo Cho, J. Hun Hah, Tack‐Kyun Kwon, Myung‐Whun Sung, Kwang Hyun Kim

    Background: Pyriform sinus fistula is a rare brachial pouch anomaly. However, it is difficult and risky to remove the fistula tract completely. Circumferential chemocauterization of the internal opening with trichloroacetic acid (TCA) for pyriform sinus fistula is simple, reproducible, reliable, and causes less morbidity. The aim of this study was to determine the feasibility of TCA chemocauterization for pyriform sinus fistula.Methods: This retrospective study enrolled 44 patients who were diagnosed with pyriform sinus fistula and underwent TCA chemocauterization. We retrospectively reviewed the medical records of the patients to obtain their demography as well as treatment outcomes for them.Results: The success rate of treatment for pyriform sinus fistula after the first TCA chemocauterization was 77.3% (34/44) and the cumulative success rate after the second treatment was 93.2% (41/44). There was no complication such as vocal fold palsy after TCA chemocauterization.Conclusions: It is suggested that TCA chemocauterization can be a reasonable first‐line treatment for pyriform sinus fistula. © 2012 Wiley Periodicals, Inc. Head Neck, 2013


  • Open Access

    Clinical Analysis of Acinic Cell Carcinoma in Parotid Gland

    by Wonjae Cha, Min-Su Kim, Jae-Chul Ahn, Sung-Woo Cho, Woongsang Sunwoo, Chang Myeon Song, Tack-Kyun Kwon, Myung-Whun Sung, Kwang Hyun Kim

    Acinic cell carcinoma (AciCC) is a rarely encountered malignancy in parotid gland. Because AciCC is rare and was recently recognized as the entity of malignancy, AciCC has been difficult to study. We aimed to analyze the diagnosis and treatment experience for this malignancy in our hospital. We retrospectively reviewed medical records of the 20 patients with AciCC of parotid gland diagnosed from 1990 to 2009. The preoperative computed tomography scan, preoperative fine needle aspiration cytology (FNAC) and intraoperative frozen section results were compared with the final diagnosis. The survival and recurrence were analyzed with the cancer stages and treatment modalities. There were 10 males and 10 females, with a mean age of 44.4 years, ranging 8-77 years. The AJCC tumor stage distributions of the patients were 70%, 15%, and 15% for stages I, II, and IV, respectively. The sensitivity of FNAC and intraoperative frozen section was 26.7% and 50.0% respectively. The 10-year survival rate was 90.9% with a mean follow-up of 111 months, ranging 17-251 months. The 10-year disease free survival rate was 74.2% and the mean duration of recurrence from initial surgery was 92.3 months. AciCC of the parotid gland is a rare malignancy that has features of less aggressive behavior, and good prognosis. Intraoperative frozen section examination may be helpful in the diagnosis of AciCC of the parotid gland because of the low sensitivity of preoperative computed tomography scan and FNAC. Surgery with adjuvant postoperative radiotherapy is satisfactory for disease control.


  • Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis

    by Young Ho Jung, J. Hun Hah, Myung-Whun Sung, Kwang Hyun Kim, Soo Youn Cho, Yoon Kyung Jeon

    Objectives/Hypothesis: Sodium/iodide symporter (NIS) is a glycoprotein which is related to the concentration of radioiodine in thyroid cancer. Glucose transporter‐1 (Glut‐1) and hexokinases (HK) are glycoproteins related to glucose metabolism (i.e., uptake and phosphorylation) in various cancers. The aim of this study was to determine the immunohistochemical patterns of expression and mutual relationships between NIS, Glut‐1, HK I, and HK II in primary thyroid tumors and synchronous cervical metastatic tumors. Study Design: Retrospective experimental study. Methods: Nine cases of follicular carcinomas, sixteen cases of papillary carcinomas, and four cases of anaplastic carcinomas were included. The immunohistochemical staining intensities were categorized (scored) as negative (0), weak (1), positive (2), or strongly positive (3) and dichotomized as a negative/weak (scores 0 or 1) or positive expression (scores 2 or 3). Results: NIS had a positive expression in good prognostic types of thyroid carcinomas, such as follicular carcinomas, more often, while having a positive expression in poor prognostic types of thyroid carcinomas, such as anaplastic carcinomas (P = .033) less often; HK I had the opposite pattern of expression (P = .033). Primary thyroid tumors and corresponding synchronous cervical metastatic tumors had a similar pattern of expression for NIS, HK I, and HK II. NIS had a reciprocal relationship with HK I as compared to Glut‐1 with respect to staining intensity on each primary tumor (P = .040). Conclusion: Reciprocal staining pattern of NIS and HK I on primary tumors is related to the staining pattern of NIS and HK I on synchronous as well as occult cervical metastatic tumors. Laryngoscope, 119:541–548, 2009


    • 1 January 2009
      • Vol. 29  (1) , 255-9

    Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.

    by Jae Jin Lee, J. Hun Hah, Seock-Ah Im, Si-Young Kim, Myung-Whun Sung, Kwang Hyun Kim, Dae Soeg Heo

    This study evaluated the effect of limited surgery following neoadjuvant chemotherapy compared to radical surgery in SCC VII (squamous cell cancer) tumor-bearing syngeneic C3H/HeJ mice. Mice showing a tumor response to cisplatin and 5-fluorouracil therapy were divided into three groups: radical surgery, with a 5 mm margin from the original tumor, group (A); limited surgery of 5 mm margin from the residual tumor, group (B); and very limited surgery with no margin from the residual tumor, group (C). The number of mice was 13 (group A), 12 (group B) and 12 (group C). No recurrence developed except in one mouse in group C. Three mice died in group A, one in group B and one in group C from perioperative complications. By intent-to-treat analysis, the survival was not significantly different among the three groups (p = 0.64), or between group A and B (p = 0.33). The outcome of limited surgery was comparable to radical surgery after neoadjuvant chemotherapy in the mouse model of head and neck cancer.


  • Sclerotherapy for Congenital Lesions in the Head and Neck

    by Kwang Hyun Kim, Myung‐Whun Sung, Jong‐Lyel Roh, Moon Hee Han

    OBJECTIVES: This study retrospectively reviews the results of sclerotherapy using several sclerosants for congenital lesions of the head and neck.METHODS AND PATIENTS: Between May 1990 and May 2002, patients with lymphatic malformations were treated by sclerotherapy; 10 with bleomycin, and 25 with OK‐432. OK‐432 sclerotherapy was also applied in 9 patients with plunging ranula and in 1 patient with branchial anomaly. Percutaneous sclerotherapy with ethanolamine oleate was used in 29 patients with venous malformations, and 28 patients with pyriform sinus fistula were treated by trichloroacetic acid chemocauterization.RESULTS: Overall, two thirds of patients with these lesions showed marked to complete response. One case of mortality occurred in the bleomycin sclerotherapy group. However, no major complications by other sclerosants were found. In lymphatic malformations, history of excision before sclerotherapy was a poor prognostic factor.CONCLUSION: Sclerotherapy using these sclerosants is a safe and effective primary treatment for congenital lesions in the head and neck.